FTC challenges second settlement between Endo and Impax
Endo Pharmaceuticals abandoned its plans to re-enter the market for an opioid painkiller after concluding it would be more profitable to split monopoly profits with Impax Laboratories, the Federal Trade Commission has alleged.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10